Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
HAMPTON, N.J., Feb. 18, 2016 -- Celldex Therapeutics, Inc. (Nasdaq:CLDX) will release fourth quarter and year-end 2015 financial results on Thursday, February 25, 2016 before the U.S. financial markets open. Celldex executives will host a conference call at 8:00 a.m. EST on the same day to discuss 2015 financial and business results and to provide an update on key 2016 objectives.
The conference call and presentation will be webcast live over the Internet and can be accessed by going to the "Events & Presentations" page under the "Investors & Media" section of the Celldex Therapeutics website at www.celldex.com. The call can also be accessed by dialing (866) 743-9666 (within the United States) or (760) 298-5103 (outside the United States). The passcode is 50465153.
A replay of the call will be available approximately two hours after the live call concludes through March 3, 2016. To access the replay, dial (855) 859-2056 (within the United States) or (404) 537-3406 (outside the United States). The passcode is 50465153. The webcast will also be archived on the Company's website.
About Celldex Therapeutics, Inc.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. Visit www.celldex.com.
Contact Sarah Cavanaugh Vice President of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3161 [email protected] Charles Liles Manager of Investor Relations & Corp Communications Celldex Therapeutics, Inc. (781) 433-3107 [email protected]
